Genmab — December 2018

[Budweis]

lidt mål for 2019 .. FDA decision on Phase III MAIA & CASSIOPEIA multiple myeloma (MM) submission Phase III COLUMBA MM subcutaneous (SC) daratumumab efficacy analysis Optimize ofatumumab » Phase III ASCLEPIOS I & II relapsing multiple sclerosis SC ofatumumab value study completion and reporting Maximize tisotumab » Phase II tisotumab vedotin recurrent/metastatic cervical cancer study vedotin progress enrollment complete by mid year

[Budweis]

Phase II enapotamab vedotin expansion cohort efficacy analysis » Phase I/II HexaBody-DR5/DR5 initial clinical data » Phase I/II DuoBody-CD3xCD20 clinical data dose escalation cohorts » File INDs or CTAs for 3 new products

[JKY_VH]

Omkrin MRD-negativitet står der i Børsens artikel "Dr. Saad Usmani sagde, at tal for MRD-negativitet fra Maia-studiet nok ville ligne resultater fra tidligere studier og være tre-fire gange bedre end standardbehandling. " God Morgen:-)

[bibob]

Thestrup 07.18. Det er sikkert det artiklen i Børsen idag hentyder til.

[GeorgeBest]

Legend CAR-T. Nok ikke overvældende? https://twitter.com/nbahlis/status/1069753489713065984?s=21

[GeorgeBest]

KRd bedre end VRd. Men KRd må også være en af de dyre https://twitter.com/ninashah33/status/1069726863801573377?s=21

[GeorgeBest]

AMG420 får generelt mange positive kommentarer https://twitter.com/noopurrajemd/status/1069785252837515264?s=21

[Jazzz]

Dejlig positiv dækning i børsen her til morgen

[bibob]

Ser ud til at bb21217 bliver overhalet indenom af AMG420. https://www.fiercebiotech.com/biotech/ash18-new-data-can-t-lift-bluebird-bio-s-depressed-shares?mkt_tok=eyJpIjoiTlRoak1qa3lNVE5pTlRjMSIsInQiOiJsc1B2YWVicmljUjZsM0QrWHNxUTFMK290aEQraVFVbSt5VWVyU01xNlBXVm82NU5qbitKSjczNDRTR3QxUVQ0WFhyemphZFlWbEdwdldpWkROcnQrRG1YM1FhQkdObFh3SDhlR1gybUV4UjUzWkZKaVU1U2ZYMkVSXC9ac25mRDMifQ%3D%3D&mrkid=41140432

[E_L]

DARA was also analyzed as a maintenance after D-VMP treatment, and this was shown to have an effect on the quality of responses, Mateos adds. https://www.youtube.com/watch?v=gPmrBRINuYQ

[Solsen]

Da jeg læste data fra AMG420 synes jeg det lignede en reportage fra en stor trafikulykke. Mange sideeffect og discontinued pts.

[bibob]

De er heller ikke trygge ved bb21217.

[bibob]

Det kan vare længere før Dara får rigtig konkurrence.

[bibob]

Mon ikke vi snart kommer til at høre mere til FATE Therapeutics. Lyder lovende. https://www.fiercebiotech.com/research/off-shelf-cell-therapy-for-cancer-fate-therapeutics-to-make-its-case-at-ash?mkt_tok=eyJpIjoiTlRoak1qa3lNVE5pTlRjMSIsInQiOiJsc1B2YWVicmljUjZsM0QrWHNxUTFMK290aEQraVFVbSt5VWVyU01xNlBXVm82NU5qbitKSjczNDRTR3QxUVQ0WFhyemphZFlWbEdwdldpWkROcnQrRG1YM1FhQkdObFh3SDhlR1gybUV4UjUzWkZKaVU1U2ZYMkVSXC9ac25mRDMifQ%3D%3D&mrkid=41140432

[E_L]

Dr. Luciano Costa presents an overview of the top multiple myeloma research at ASH 2018
https://www.youtube.com/watch?v=20Snfn89iyQ&feature=youtu.be

[AaBforever]

Ja der er ikke meget firework over den i dag..:-(

[AaBforever]

Måske en lille fuser...

[E_L]

i could really use a good objective summary of the Car-t and BCMA data presented… I see some excitement but also a lot of toxicity or even 'lost' patients…

[jkj]

Maia præsentation kl. 16.30

[concillado]

Alt godt til dem som venter (og er tro mod deres investeringsstrategi): https://play.borsen.dk/klip/5c0565b4595ab4f00a32b277/genmab-analyse_fuld_fokus_paa_darzalex-data_senere_i_dag.html